Thu, Dec 25, 2014, 5:57 PM EST - U.S. Markets closed for Christmas

Recent

% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • itsyou@bellsouth.net itsyou Aug 20, 2014 12:05 PM Flag

    DJ Bristol, Celgene to Test Immuno/Chemo Cocktail -- Market Talk

     

    20-AUG-2014 11:02AM, DJ Bristol, Celgene to Test Immuno/Chemo Cocktail -- Market Talk

    11:02 EDT - The agreement between Bristol (BMY) and Celgene (CELG) to collaborate on a cancer trial illustrates how quickly companies are moving to test new immunotherapy agents in combination with other treatments. BMS' nivolumab is among an emerging class of agents called checkpoint inhibitors which unleash the immune system to attack cancer. They've shown the most promise against melanoma. Nivo isn't yet FDA-approved, but the plan to test it with CELG's Abraxane against Her-2 negative metastatic breast cancer and other tumors reflects hope that such drug cocktails will help broaden immunotherapy's benefits to a variety of cancers. CELG climbs 1.7%, hitting a fresh record high, while BMY is off 0.2%

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
GALE
1.49-0.02(-1.32%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.